What's new
This page lists items that we have published for the first time or updated in the last 7, 30 or 60 days. Use the filters to narrow results by audience, product type, content type or topic.
You can also stay informed by:
- subscribing to our updates to receive same-day notification emails on safety information, scheduling updates or media releases.
- checking for open consultations.
- joining any upcoming events.
This page is in Beta testing. We welcome your feedback and suggestions as we look to improve this page.
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topic
- Advertising (3)
- Breast implant hub (1)
- Clinical trials (1)
- Committees and advisory bodies (1)
- Compliance and enforcement (8)
- Import and export (4)
- Labelling and packaging (1)
- Legislation (1)
- Manufacturing (2)
- Medicinal cannabis hub (1)
- Safety monitoring and information (17)
- Shortages and supply disruptions (9)
- Sunscreens (4)
- Unique Device Identification (UDI) hub (4)
- Urogynaecological (transvaginal) surgical mesh hub (1)
- Vaping hub (1)
- Weight loss products (1)
What's new
73 result(s) found, displaying 1 to 25
-
Media releasesThe TGA, assisted by the New South Wales Police Force, has conducted targeted enforcement action across 2 sites in south-west Sydney.
-
DatasetSearch approvals to import and supply medicines not in the Australian Register of Therapeutic Goods (ARTG) to address medicine shortages.
-
PageInformation on issues relating to sunscreens using the same base formulation as Ultra Violette Lean Screen SPF 50+ following the recent CHOICE SPF testing of a range of sunscreens on the Australian market.
-
Media releasesTwo Victorian men and one woman have been charged following a joint investigation into an alleged criminal syndicate importing Performance and Image Enhancing Drugs (PIEDs) into Australia.
-
Safety alertsWe are advising consumers that Artri Ajo King tablets may pose a serious risk to your health and should not be taken.
-
DatasetSearch our database of sponsor-requested cancellations from the ARTG.
-
BlogPatient information materials are required to be supplied with implantable and active implantable medical devices in Australia. Abby’s story highlights the practical importance of the patient information materials.
-
PageNew shortage expected during May 2026.
-
Market actionsGlaxoSmithKline (GSK) Australia Pty Ltd is issuing a product correction for certain batches of their Flixotide and Pavtide Accuhalers as a small number of Accuhalers may not automatically reload the next dose.
-
Meeting statementsThe 88th meeting of the Advisory Committee on Medical Devices (ACMD) was held on 11 December 2025.
-
DatasetSearch companion diagnostics (CDx) we have approved for supply in Australia.
-
PageThe TGA has completed a post-market review of all energy-based devices used for vaginal rejuvenation included in the Australian Register of Therapeutic Goods (ARTG).
-
News articlesWe are providing an updated statement on the IChEMS and the prohibitions relevant to chemicals such as certain PFAS chemicals, UV-328 and Dechlorane Plus
-
PageUnique Device Identification (UDI) webinars cover a range of topics including introductory UDI information, adoption in healthcare and software support for UDI.
-
PageThe EU MDR transition web publication service provides notifications to providers and consumers going through low-risk changes, as part of the transition.
-
GuidanceGuidance on the mandatory requirements for reporting current and anticipated reportable medicine shortages and discontinuations in Australia.
-
Safety alertsWe are concerned about the rise in the import, supply, compounding and advertising of unapproved peptide products and the potential safety risks associated with these goods.
-
PageRead the latest enhancements and fixes to the Australian UDI Database.
-
Australian public assessment report (AusPar)Kavigale (sipavibart) has been approved for the pre-exposure prophylaxis of COVID-19 in adults and adolescents aged 12 years and older weighing at least 40 kg who are immunocompromised due to a medical condition or receipt of immunosuppressive medications or treatments.
-
PageHow we work with other regulators and organisations.
-
PageInformation on the TGA Laboratories testing program for therapeutic goods.
-
PageThe TGA Laboratories perform a range of activities to ensure therapeutic goods are of an acceptable standard
-
PageThe TGA Laboratories perform a range of activities to ensure therapeutic goods are of an acceptable standard
-
PageA list of Artificial Intelligence (AI) enabled medical devices included in the Australian Register of Therapeutic Goods (ARTG).
-
Australian public assessment report (AusPar)Briumvi (ublituximab) has been approved for the treatment of adult patients with relapsing forms of multiple sclerosis with active disease defined by clinical or imaging features.